BTF's 2024 Updates on Hematology and Oncology, El Paso

El Paso, TX US
July 20, 2024

This CME-accredited oncology conference, BTF's 2024 Updates on Hematology and Oncology, El Paso, is designed to improve the care of cancer patients by educating clinicians involved in cancer care.

The expert faculty will present a comprehensive overview of recent updates in hematology and oncology. The program will feature in-depth discussions and analyses of the latest scientific discoveries and advancements. Faculty will contextualize these findings within clinical practice and explore their potential to alter current standards of care. This conference is designed for physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals, providing them with the latest updates in the field. Emphasizing a multidisciplinary approach, it will showcase the integration of new advancements into patient-centered care.

Target Audience

  • Medical oncologists
  • Radiation oncologists
  • Surgical oncologists
  • Oncology residents/fellows
  • Oncology NPs/PAs
  • Oncology pharmacists
  • Oncology nurses

Organizing Committee: 

Course Director:

Binay Shah, MD, MHA - Binaytara Foundation

Conference Chair:

Ines Sanchez-Rivera, MD - Texas Oncology

Learning Objectives

At the conclusion of the activity, participants will be able to:

  1. Discuss new and updated treatment options for patients with hematologic malignancies and solid tumors
  2. Identify side effects, indications, and contra-indications of therapies used to diagnose and treat cancers
  3. Explain how to effectively manage side-effects associated with cancer treatment

Hotel Information

If you are attending this meeting and need to reserve a hotel room, please book your room at the Marriott El Paso by calling 915-774-6934 to take advantage of the discounted group rate of $129 per night plus applicable taxes and fees.

GLOBAL ONCOLOGY PROJECT

Click this link to learn more about our ongoing project building a 200-bed cancer hospital in Nepal: https://binayfoundation.org/cancer-hospital/

Course summary
Available credit: 
  • 5.75 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.75 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 5.75 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 5.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 5.75 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 5.75 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 5.75 Contact Hours.
Course opens: 
04/19/2024
Course expires: 
12/31/2024
Event starts: 
07/20/2024 - 8:00am PDT
Event ends: 
07/20/2024 - 4:00pm PDT
Cost:
$150.00

July 20th, 2024

All times are listed in Mountain Time (MT)

07:00 AM – 08:00 AM  Registration, Breakfast, & Exhibits


08:00 AM – 08:05 AM  Welcome

08:05 AM – 08:20 AM  Binaytara Foundation's Efforts in Improving Cancer Care Disparities - Binay Shah, MD, MHA


08:20 AM – 09:35 AM  Session 1 - Hematologic Malignancies

Session Chair: Nanda K. Gopalan, MD

08:20 AM – 08:35 AM  MDS/Leukemias - Sharad Khurana, MD, MSc

08:35 AM – 08:50 AM  Multiple Myeloma - Adeel Khan, MD, MPH, MS

08:50 AM – 09:05 AM  Lymphoma & CLL - Alexey Danilov, MD, PhD

09:05 AM – 09:35 AM  Case-Based Discussion 


09:35 AM – 10:05 AM  Break & Exhibits


10:05 AM – 10:55 AM  Session 2 - Thoracic Oncology

Session Chair: Mathews L. George, MD

10:05 AM – 10:20 AM  Early-Stage Lung Cancer - Ira Surolia, MD

10:20 AM – 10:35 AM  Advanced Lung Cancer - Lei Deng, MD

10:35 AM – 10:55 AM  Case-Based Discussion 


10:55 AM – 12:10 PM  Session 3 - General Oncology

Session Chair: Joshua M. Rodriguez, MD, PharmD

10:55 AM – 11:15 AM  ctDNA in Lung Cancer - Moises Harari Turquie, MD

11:15 AM – 11:35 AM  Head and Neck Cancer - Luana G. Sousa, MD

11:35 AM – 11:55 AM  Cellular Therapy - Shashank Cingam, MD

11:55 AM – 12:10 PM  Case-Based Discussion


12:10 PM – 01:10 PM  Lunch & Exhibits


01:10 PM – 02:00 PM  Session 4 - Genitourinary Cancer

Session Chair: Juan Herrada, MD, FACP

01:10 PM – 01:25 PM  Kidney and Prostate Cancer - Benjamin Maughan, MD, PharmD

01:25 PM – 01:40 PM  Bladder Cancer - Arlene O. Siefker-Radtke, MD

01:40 PM – 02:00 PM  Case-Based Discussion 


02:00 PM – 02:50 PM  Session 5 - GI Cancer

Session Chair: Monica Adriana Diaz, MD

02:00 PM – 02:15 PM  Upper GI Malignancies - Timothy Brown, MD

02:15 PM – 02:30 PM  Lower GI Malignancies - Ronan Hsieh, MD

02:30 PM – 02:50 PM  Case-Based Discussion 


02:50 PM – 03:20 PM  Break & Exhibits


03:20 PM – 04:10 PM  Session 6 - Breast Cancer

Session Chair: Ines Sanchez-Rivera, MD, FACP

03:20 PM – 03:45 PM  Recent Updates in Breast Cancer - Christos Vaklavas, MD

03:45 PM – 04:10 PM  Case-Based Discussion - Arya Mariam Roy, MBBS


04:10 PM  Adjourn

Marriott El Paso
1600 Airway Blvd
El Paso, TX 79925
United States

If you are attending this meeting and need to reserve a hotel room, please book your room at the Marriott El Paso by calling 915-774-6934 to take advantage of the discounted group rate of $129 per night plus applicable taxes and fees.

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

 

Conference Chair(s)

Ines Sanchez Rivera, Area and Regional Medical Director Of Texas Oncology El Paso

has no relevant financial relationships to disclose at this time.
Session Chair(s)

Monica Diaz

has no relevant financial relationships to disclose at this time.

Nanda Gopalan, MD

has no relevant financial relationships to disclose at this time.

Juan Herrada, Speaker

has no relevant financial relationships to disclose at this time.

Joshua Rodriguez

has no relevant financial relationships to disclose at this time.

Ines Sanchez Rivera, Area and Regional Medical Director Of Texas Oncology El Paso

has no relevant financial relationships to disclose at this time.
Speaker/Topic Presenter(s)

Timothy Brown, MD MSCE

has no relevant financial relationships to disclose at this time.

Shashank Cingam

has no relevant financial relationships to disclose at this time.

Alexey Danilov, MD, PhD

has a financial relationship (Independent contractor) with Astra Zeneca;.
has a financial relationship (Independent contractor) with Lilly;.
has a financial relationship (Grant Or Contract) with Nurix;.
has a financial relationship (Grant Or Contract) with Bayer;.
has a financial relationship (Independent contractor) with Beigene;.
has a financial relationship (Grant Or Contract) with MEI;.
has a financial relationship (Independent contractor) with Abbvie;.

Lei Deng, MD

has a financial relationship (Independent contractor) with Regeneron;.
has a financial relationship (Independent contractor) with Bristol Meyer Squibb;.
has a financial relationship (Travel) with MJH Life Sciences;.

mathews george

has no relevant financial relationships to disclose at this time.

Moises Harari Turquie, MD

has no relevant financial relationships to disclose at this time.

Ronan Hsieh, MD, MS

has no relevant financial relationships to disclose at this time.

Adeel Khan, Adeel Khan, MD, MPH, MS

has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Janssen;.

Sharad Khurana, MD, MSc

has no relevant financial relationships to disclose at this time.

Benjamin Maughan, M.D., PharmD

has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Independent contractor) with Tempus;.
has a financial relationship (Independent contractor) with Peloton Therapeutis;.
has a financial relationship (Independent contractor) with Xencor;.
has a financial relationship (Independent contractor) with AVEO Oncology;.
has a financial relationship (Independent contractor) with Clovis;.
has a financial relationship (Independent contractor) with Bayer Oncology;.
has a financial relationship (Independent contractor) with Telix;.
has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Independent contractor) with Bristol-Myers Squibb;.
has a financial relationship (Independent contractor) with Exelixis;.
has a financial relationship (Independent contractor) with Sanofi;.
has a financial relationship (Independent contractor) with Astellas;.
has a financial relationship (Independent contractor) with Merck;.
has a financial relationship (Independent contractor) with Lilly;.
has a financial relationship (Independent contractor) with NCCN;.
has a financial relationship (Independent contractor) with Abbvie;.

Arlene Siefker-Radtke, MD

has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with G1 Therapeutics;.
has a financial relationship (Professional Services) with Loxo;.
has a financial relationship (Professional Services) with Seattle Genetics;.
has a financial relationship (Grant Or Contract) with Janssen;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with Immunomedics;.
has a financial relationship (Professional Services) with Nektar Therapeutics;.
has a financial relationship (Grant Or Contract) with Bristol Myers Squibb;.
has a financial relationship (Grant Or Contract) with Nektar Therapeutics;.
has a financial relationship (Professional Services) with Bristol Myers Squibb;.
has a financial relationship (Professional Services) with Ideeya Biosciences ;.
has a financial relationship (Professional Services) with Mirati;.
has a financial relationship (Grant Or Contract) with Basilea Pharmaceutica;.
has a financial relationship (Grant Or Contract) with Millennium;.
has a financial relationship (Professional Services) with Bavarian Nordic;.
has a financial relationship (Professional Services) with Gilead;.
has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with Taiho;.
has a financial relationship (Grant Or Contract) with Merck;.

Luana Sousa

has no relevant financial relationships to disclose at this time.

Ira Surolia, MD, MPH

has a financial relationship (Other) with Curio Bioscience ;.
has a financial relationship (Other) with Cardinal Healthcare ;.
has a financial relationship (Other) with MJH Healthcare ;.

Christos Vaklavas, M.D., Associate Professor

has a financial relationship (Employment) with Flatiron;.
has a financial relationship (Professional Services) with Daiichi Sankyo;.
has a financial relationship (Financial Support) with Pfizer;.
has a financial relationship (Financial Support) with CytomX;.
has a financial relationship (Professional Services) with SeaGen;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Financial Support) with AstraZeneca;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Financial Support) with H3 Biomedicine;.
has a financial relationship (Professional Services) with Guidepoint;.
has a financial relationship (Professional Services) with Gilead;.
has a financial relationship (Financial Support) with SeaGen;.
Case Presenter(s)

Nanda Gopalan, MD

has no relevant financial relationships to disclose at this time.

Arya Mariam Roy, MD

has no relevant financial relationships to disclose at this time.

Available Credit

  • 5.75 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.75 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 5.75 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 5.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 5.75 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 5.75 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 5.75 Contact Hours.

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

 

Price

Cost:
$150.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.